New targeted drug shows promise for Hard-to-Treat cancers

NCT ID NCT03006172

Ongoing Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participants will receive the drug by mouth, and researchers will monitor side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SOLID TUMOR

Contacts and locations

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Institut Bergonie

Bordeaux, 33076, France
Institut Gustave Roussy

Villejuif, 94805, France
Massachusetts General Hospital.

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10017, United States
Princess Margaret Hospital

Toronto, Ontario, M5G2M9, Canada
Royal Marsden Hospital - London

London, SW3 6JJ, United Kingdom
Royal Marsden Hospital - Surrey

Surrey, Sutton, SM2 5PT, United Kingdom
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
St Bartholomew's Hospital

London, EC1 A7BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.